批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
>>>原始批准或临时批准<<<
| 审批日期 | 提交号 | 审批结论 | 提交分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
| 2005/12/01 |
ORIG-1(原始申请) |
Approval |
Type 1 - New Molecular Entity |
PRIORITY
;Orphan
|
|
|
>>>补充申请<<<
| 审批日期 | 提交号 | 审批结论 | 补充类别或审批类型 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
| 2023/08/28 |
SUPPL-26(补充) |
Approval |
Labeling-Package Insert |
N/A
;Orphan
|
|
|
| 2021/05/20 |
SUPPL-25(补充) |
Approval |
Labeling-Container/Carton Labels |
STANDARD
;Orphan
|
|
|
| 2020/07/09 |
SUPPL-24(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2020/06/19 |
SUPPL-22(补充) |
Approval |
Labeling-Patient Package Insert,Labeling-Package Insert |
STANDARD
;Orphan
|
|
|
| 2020/04/02 |
SUPPL-23(补充) |
Approval |
Labeling-Package Insert |
STANDARD
;Orphan
|
|
|
| 2018/12/06 |
SUPPL-20(补充) |
Approval |
Labeling-Package Insert |
STANDARD
;Orphan
|
|
|
| 2018/12/06 |
SUPPL-19(补充) |
Approval |
Labeling-Package Insert |
STANDARD
;Orphan
|
|
|
| 2017/12/22 |
SUPPL-18(补充) |
Approval |
Efficacy-Labeling Change With Clinical Data |
STANDARD
;Orphan
|
|
|
| 2014/12/02 |
SUPPL-17(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
| 2013/11/22 |
SUPPL-16(补充) |
Approval |
Efficacy-New Indication |
PRIORITY
;Orphan
|
|
|
| 2013/10/30 |
SUPPL-15(补充) |
Approval |
Labeling-Package Insert |
STANDARD
;Orphan
|
|
|
| 2013/06/11 |
SUPPL-14(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2012/08/24 |
SUPPL-13(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2011/10/14 |
SUPPL-12(补充) |
Approval |
Labeling-Package Insert,Labeling-Package Insert |
STANDARD
|
|
|
| 2011/03/22 |
SUPPL-11(补充) |
Approval |
Labeling |
STANDARD
|
|
|
| 2010/10/26 |
SUPPL-9(补充) |
Approval |
Labeling-Package Insert |
UNKNOWN
|
|
|
| 2010/10/26 |
SUPPL-8(补充) |
Approval |
Labeling |
STANDARD
|
|
|
| 2007/11/16 |
SUPPL-7(补充) |
Approval |
Efficacy-New Indication |
PRIORITY
|
|
|
| 2007/11/16 |
SUPPL-6(补充) |
Approval |
Efficacy-New Indication |
PRIORITY
|
|
|
| 2007/11/16 |
SUPPL-5(补充) |
Approval |
Efficacy-New Indication |
PRIORITY
|
|
|
| 2007/11/16 |
SUPPL-4(补充) |
Approval |
Efficacy-New Indication |
PRIORITY
|
|
|
| 2007/03/05 |
SUPPL-3(补充) |
Approval |
Labeling |
STANDARD
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
>>>活性成分:SORAFENIB TOSYLATE; 剂型/给药途径:TABLET;ORAL; 规格:EQ 200MG BASE; 治疗等效代码:AB<<<
| 申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
| 021923 |
001 |
NDA |
NEXAVAR |
SORAFENIB TOSYLATE |
TABLET;ORAL |
EQ 200MG BASE |
Prescription |
Yes |
Yes |
AB |
2005/12/20
|
BAYER HLTHCARE |
| 207012 |
001 |
ANDA |
SORAFENIB TOSYLATE |
SORAFENIB TOSYLATE |
TABLET;ORAL |
EQ 200MG BASE |
Prescription |
No |
No |
AB |
2020/09/10
|
MYLAN |
| 209567 |
001 |
ANDA |
SORAFENIB TOSYLATE |
SORAFENIB TOSYLATE |
TABLET;ORAL |
EQ 200MG BASE |
Prescription |
No |
No |
AB |
2020/11/12
|
TEVA PHARMS USA INC |
| 216073 |
001 |
ANDA |
SORAFENIB TOSYLATE |
SORAFENIB TOSYLATE |
TABLET;ORAL |
EQ 200MG BASE |
Prescription |
No |
No |
AB |
2022/06/07
|
DR REDDYS |
| 209050 |
001 |
ANDA |
SORAFENIB TOSYLATE |
SORAFENIB TOSYLATE |
TABLET;ORAL |
EQ 200MG BASE |
Prescription |
No |
No |
AB |
2022/11/09
|
YABAO PHARM |
| 217095 |
001 |
ANDA |
SORAFENIB TOSYLATE |
SORAFENIB TOSYLATE |
TABLET;ORAL |
EQ 200MG BASE |
Prescription |
No |
No |
AB |
2023/04/12
|
TORRENT |
| 212228 |
001 |
ANDA |
SORAFENIB TOSYLATE |
SORAFENIB TOSYLATE |
TABLET;ORAL |
EQ 200MG BASE |
Discontinued |
No |
No |
AB |
2025/01/27
|
APOTEX |